This result is in contrast with that observed in patients with germline CDKN2A variants who received immune-checkpoint inhibitors, as in the case of immunotherapy, the high mutational burden may favor anti-tumor responses [5]. The gene discussed is CDKN2A; the disease is neoplasm.